Editas Medicine Inc 2024年度报告

EDITAS MEDICINE, INC.(Exact name of registrant as specified in its charter) __________________________________________________ (617)401-9000(Registrant’s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesoNox Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesoNox Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or forsuch shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of thischapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. Seedefinitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting underSection 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.o If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error topreviously issued financial statements.o Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executiveofficers during the relevant recovery period pursuant to §240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesoNox As of June 28, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s Common Stock held by non-affiliatesof the registrant was approximately $383,847,152based upon the closing price of the registrant’s Common Stock on June 28, 2024. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant’s fiscalyear ended December31, 2024 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Editas Medicine, Inc.TABLE OF CONTENTS PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II 103 Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities103Item 6.[Reserved]104Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations104Item 7A.Quantitative and Qualitative Disclosures About Market Risk116Item 8.Financial Statements and Supplementary Data117Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure152Item 9A.Controls and Procedures152Item 9B.Other Information152Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections153 PART III Item 10.Directors, Executive Officers and Corporate Governance154Item 11.Executive Compensation154Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters154Item 13.Certain Relationships and Related Transactions, and Director Independence154Item 14.Principal Accounting Fees and Services154 PART IV Item 15.Exhibits and Financial Statement Schedules155Item 16.Form 10-K Summary158 SIGNATURES159 References to Editas Throughout this Annual Report on Form 10-K, the “Company,” “Editas,” “Editas Medicine,” “we,” “us,” and “our,” except where thecontext requires otherwise, refer to Editas Medicine, Inc. and its consolidated subsidiary, and “our board of directors” refers to the board ofdirectors of